Meeting
2019 Genitourinary Cancers Symposium
An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma.
Authors
Eric Jonasch
The University of Texas MD Anderson Cancer Center, Houston, TX
Eric Jonasch , Eric Kristopher Park , Sanjay Thamake , Mohammad Hirmand , W. Marston Linehan , Ramaprasad Srinivasan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT03401788
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS680)
DOI
10.1200/JCO.2019.37.7_suppl.TPS680
Abstract #
TPS680
Poster Bd #
K11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma.
First Author: David F. McDermott
Poster
2021 ASCO Annual Meeting
Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
First Author: Ramaprasad Srinivasan
Poster
2021 Genitourinary Cancers Symposium
Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
First Author: Othon Iliopoulos
Poster
2023 ASCO Annual Meeting
LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).
First Author: David F. McDermott